Document:

EX-10.19

 Exhibit 10.19 

CONFIDENTIAL TREATMENT REQUESTED 

Paid-up License Agreement 
 THIS AGREEMENT
made and entered into as of March 6, 2013 by and between KOKEN Co., Ltd. (hereinafter referred to as “KOKEN”) and HISTOGENICS CORPORATION (hereinafter referred to as “HISTOGENICS”). 

WITNESSETH: 
 WHEREAS, KOKEN has developed extensive technical
information related to manufacturing process of honeycomb materials (hereinafter referred to as “MATERIALS”); 
 WHEREAS, HISTOGENICS continuingly
purchases from KOKEN MATERIALS manufactured by KOKEN for clinical trial use under SUPPLY AGREEMENT dated April 1, 2003 between the parties; 
 WHEREAS,
HISTOGENICS desires to obtain a non-exclusive right to use CONFIDENTIAL INFORMATION hereinafter defined for manufacturing MATERIALS suitable for commercial applications; and 

WHEREAS, KOKEN is willing to grant to HISTOGENICS such right under the terms and conditions hereinafter contained; 

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, the parties agree as follows: 

Article 1 (Definitions) 
 As used in this Agreement, 

 

	(1)	“CONFIDENTIAL INFORMATION” means any and all technical information and know-how owned by KOKEN which relate to manufacturing process of MATERIALS and which will be disclosed by KOKEN hereunder ****.
CONFIDENTIAL INFORMATION includes the following information and 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

  
 documentation, but does
not include any technical information related to collagen products; 
  

	 	•	 	a flow chart of manufacturing process of MATERIALS. 

  

	 	•	 	any information HISTOGENICS may access during FACTORY TOUR hereinafter defined. 

  

	(2)	“FACTORY TOUR” means the factory tour at KOKEN Tsuruoka Factory now scheduled to be conducted from March 11 to 15, 2013. 

Article 2 (Grant of License) 
 Subject to the terms and
conditions herein contained, KOKEN hereby grants to HISTOGENICS a non-exclusive and non-transferable right without the right to sublicense to use CONFIDENTIAL INFORMATION for manufacture of MATERIALS suitable for commercial applications. 

Article 3 (Disclosure of CONFIDENTIAL INFORMATION) 
 KOKEN will
disclose CONFIDENTIAL INFORMATION to HISTOGENICS at FACTORY TOUR. 
 Attendant at FACTORY TOUR shall be limited to HISTOGENICS’s employees with respect
to whom KOKEN’s prior written approval has been obtained. 
 Article 4 (Payment) 

In consideration of the license granted and disclosure hereunder, HISTOGENICS shall pay to KOKEN ****, without any deduction, to the bank account designated by
KOKEN within five(5) days from the execution dated hereof. 
 Article 5 (Disclaimer of Warranties) 

HISTOGENICS confirms and agrees that CONFIDENTIAL INFORMATION is disclosed and licensed to HISTOGENICS on an “as is” basis. 

THERE ARE NO WARRANTIES BY KOKEN, WITH RESPECT TO CONFIDENTIAL INFORMATION AND LICENSE GRANTED HEREUNDER, EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES
OF MERCHANTABILITY, FITNESS FOR 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

  
 PARTICULAR PURPOSE AND NO INFRINGEMENT
OF ANY INTELLECTUAL PROPERTY RIGHT OF A THIRD PARTY. 
 Article 6 (Secrecy) 

HISTOGENICS agrees to maintain CONFIDENTIAL INFORMATION in strict confidence and protect CONFIDENTIAL INFORMATION against unauthorized disclosure or access.

 HISTOGENICS agrees not to make any disclosure of CONFIDENTIAL INFORMATION to any third party including ****, except to **** who have agreed in writing to
receive it under the terms at least so restrictive as those specified in this Agreement. 
 HISTOGENICS agrees not to apply for any patent, utility model
right or any other intellectual property right based on CONFIDENTIAL INFORMATION. 
 HISTOGENICS will ensure that its contract manufacturers use
CONFIDENTIAL INFORMATION ****. HISTOGENICS will ensure that its contract manufacturers do not use CONFIDENTIAL INFORMATION ****. 
 Article 7
(Indemnification) 
 HISTOGENICS agrees to defend, indemnify and hold harmless KOKEN, its directors, officers and employees from and against any claims,
actions or demands resulting from use of CONFIDENTIAL INFORMATION. 
 Article 8 (Termination) 

KOKEN may, without prejudice to any other rights or remedies, terminate this Agreement by giving a written notice to HISTOGENICS with immediate effect, if the
following event should occur; 
  

	(a)	if HISTOGENICS fails to make any payment to KOKEN hereunder; 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	(b)	if HISTOGENICS fails to perform any other obligation hereunder, which failure remains uncorrected for more than thirty (30) days after receipt of a written notice specifying the default; or 

 

	(c)	if HISTOGENICS files a petition in bankruptcy, or a petition in bankruptcy is filed against it, or HISTOGENICS becomes insolvent, bankrupt, or goes into liquidation or receivership. 

Upon termination of this Agreement, HISTOGENICS shall forthwith cease to use CONFIDENTIAL INFORMATION and return CONFIDENTIAL INFORMATION in tangible form to
KOKEN. 
 The provisions of Articles 5 to 7 shall survive the termination of this Agreement. 

Article 9 (Remedies) 
 HISTOGENICS acknowledges that CONFIDENTIAL
INFORMATION is proprietary and valuable to KOKEN and KOKEN may incur irreparable harm and loss as a result of HISTOGENICS’s breach of this Agreement and that in case of such breach, the monetary damages may not be an adequate remedy and KOKEN
is entitled to seek not only the monetary damages, but also injunction in addition to any other remedies available for KOKEN at law or in equity. 
 Article
10 (Assignment) 
 This Agreement or any part of this Agreement may not be assigned by either party without the prior written consent of the other party.

 “Assignment” under this Article includes any assignment due to merger, consolidation, reorganization, or otherwise. 

Article 11 (Severability of Provisions) 
 In case where any
provision of this Agreement is determined to be illegal or invalid, such illegality or invalidity shall not affect the validity and effect of the remaining provisions of this Agreement. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Article 12 (Entire Agreement and Amendment) 

This Agreement shall constitute the entire agreement and understanding of KOKEN and HISTOGENICS as to the subject matter of this Agreement and supersedes all
prior oral or written agreements, arrangements or understandings between KOKEN and HISTOGENICS. 
 This Agreement may be amended only in a writing signed by
KOKEN and HISTOGENICS. 
 Article 13 (Governing Law) 
 This
Agreement shall be governed and construed in accordance with the law of ****. 
 Article 14 (Arbitration) 

Any dispute concerning this Agreement shall be settled by arbitration conducted by three arbitrators in accordance with the **** in ****. The arbitral award
may be entered in any court having jurisdiction Over KOKEN and HISTOGENICS or their assets. Notwithstanding above, KOKEN may seek preliminary injunctive relief in any court of competent jurisdiction. 

Article 15 (Headings) 
 The headings appearing in this Agreement
are inserted for convenience of reference only and shall not form a part hereof. 
 IN WITNESS WHEREOF, KOKEN and HISTOGENICS have caused this Agreement to
be executed by their duly authorized representatives in duplicate as of the date and year first above written. 
  

					
	KOKEN Co., Ltd.	 		 	HISTOGENICS CORPORATION
			
	/s/ Yuzo Tarumi	 		 	/s/ Kevin McArdle
			
	Yuzo Tarumi	 		 	Kevin McArdle
			
	President	 		 	Chief Financial Officer
			
	Date Mar. 7, 2013	 		 	Date March 6, 2013

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.EX-10.20

 Exhibit 10.20 

CONFIDENTIAL TREATMENT REQUESTED 

AGREEMENT 
 Agreement made
and entered into as of the 22nd day of June, 2012, by and between Purpose Co., Ltd., f/k/a Takagi Sangyo Co. Ltd., and also f/k/a Takagi Industrial Co., Ltd., a Japanese corporation (“Takagi”), and Histogenics Corporation, a Delaware
corporation (“Histogenics”) (the “Agreement”). The parties agree as follows: 
 1. Introduction. Takagi and
Histogenics are parties to the following agreements and no others (the “Existing Agreements”): 
 Subscription and Business
Agreement dated July 6, 2000 
 Amendment to Subscription and Business Agreement dated September 23, 2005 

Supplemental Agreement dated May 11, 2006. 

The purpose of this Agreement is to amend, restate and otherwise terminate the Existing Agreements and replace them with this Agreement. The parties further
acknowledge that Histogenics is party to a term sheet dated February 24, 2012 with **** (the “**** Term Sheet”), a copy of which is attached hereto as Exhibit A. This Agreement is being entered into in contemplation of the Initial
Closing under the **** Term Sheet (the “Effective Date”), and this Agreement shall be in full force and effect as of the Effective Date. 

2. Termination of Existing Agreements. Upon the Effective Date, the Existing Agreements shall be of no further force and effect and
this Agreement and any other agreements attached as or contemplated by Exhibits to this Agreement shall represent the entire understanding of the parties. 

3. License of Technology. 

(a) License to Histogenics. Takagi hereby grants to Histogenics outside of Japan the perpetual (with respect to patent rights, for the
full term of each patent licensed hereunder), paid-up, worldwide, sublicensable, exclusive right under all patent rights (“Takagi Patents”) and technology (including, but not limited to, all know-how, trade secrets, copyrightable works,
design and technical information and all improvements, modifications, updates or derivatives thereof) (the “Takagi Technology”) relating to Takagi’s exogenous tissue processor as used for producing the Histogenics Product Line (as
such term is defined in Section 3(b) below), whether owned by Takagi or based upon 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 
 
 1
 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
rights held by Takagi, and whether now owned or held by Takagi or at any time following the date of this Agreement , in the Field of Use (as defined below) to (i) use, make, have made, sell,
offer for sale, and import products or services that would, but for the license granted under the Takagi Patents, infringe a valid claim of any Takagi Patent, and (ii) use, reproduce, modify and create derivative works of the Takagi Technology
for the design, development, manufacture, testing, support and commercialization of any product or service that incorporates or builds upon the Takagi Technology. The Takagi Patents hereby include, without limitation, the patent rights owned by
Takagi that are listed on Exhibit B-1 to this Agreement. The “Field of Use” consists of any applications of the Takagi Technology and Histogenics Technology (as defined below) in connection with articular cartilage, ligaments, tendons and
meniscus. Takagi retains its rights to the Takagi Technology and Takagi Patents for any applications outside the Field of Use. Takagi shall also have the right to sell its TEPs (as such term is defined below) in Section 4 to research institutes
for general but noncommercial use anywhere in the world. Takagi acknowledges that the license granted hereby gives Histogenics the right but not the obligation, to use the Takagi Technology or practice the Takagi Patents. 

(b) License to Takagi. Histogenics hereby grants to Takagi the perpetual (with respect to patent rights, for the full term of each
patent licensed hereunder), paid-up, subslicensable, exclusive right solely in Japan under all patent rights (“Histogenics Patents”) and technology (including, but not limited to, all know-how, trade secrets, copyrightable works, design
and technical information and all improvements, modifications, updates or derivatives thereof) (the “Histogenics Technology”) relating to Histogenics’ biotechnology and biomaterials, whether owned by Histogenics or based upon rights
held by Histogenics, and whether now owned or held by Histogenics or at any time following the date of this Agreement in the Field of Use to (i) use, make, have made, sell, offer for sale, and import products and services that would, but for
the license granted under the Histogenics Patents, infringe a valid claim of any Histogenics Patent, and (ii) use, reproduce, modify and create derivative works of the Histogenics Technology for the design, development, manufacture, testing,
support and commercialization of any product or service that incorporates or builds upon the Histogenics Technology. The Histogenics Patents 

  
 2 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
hereby include, without limitation, the patent rights owned by Histogenics that are listed on Exhibit B-2 to this Agreement. Histogenics retains its rights to the Histogenics Technology and
Histogenics Patents for any applications outside the Field of Use and for inside the Field of Use anywhere in the world other than Japan. Histogenics acknowledges that the license granted hereby gives Takagi the right, but not the obligation, to use
the Histogenics Technology or practice the Histogenics Patents in Japan. Notwithstanding anything to the contrary contained in the foregoing, the license rights granted to Takagi under this Section 3(b) are limited to the following
Histogenics’ products: Neocart**** (both individually and collectively, the “Histogenics Product Line”). Histogenics represents to Takagi that as of the date of this Agreement the Histogenics Product Line represents all of the
products it has currently under development. 
 4. Sale of Machines. Takagi shall continue to manufacture and sell single unit
exogenous tissue processor machines (so-called “TEPs”) to Histogenics to the extent desired by Histogenics. Prior to the commercialization of Histogenics’ first product (“Neocart”), Takagi shall sell TEPs to Histogenics at
****. Thereafter, Takagi shall sell TEPs to Histogenics at ****. Within 60 days of the execution of this Agreement, the parties shall enter into a service agreement, the form of which shall be attached to this Agreement as Exhibit C, which service
agreement shall cover the maintenance and servicing of both the existing TEPs owned by Histogenics and any additional TEPs that Histogenics may purchase from Takagi in the future. The parties agree that the service agreement shall be “industry
standard” as to its form and terms. 
 5. Reimbursement of Development Costs. The parties acknowledge that Takagi has incurred
19,572,000 YEN in costs prior to the date of this Agreement in developing a multi-unit TEP on Histogenics behalf. On the Effective Date Histogenics shall pay that amount to Takagi. Takagi acknowledges that Histogenics intends to continue the
development of a multi-unit TEP with an alternative supplier and that Histogenics shall not be liable for any future costs incurred by Takagi in developing a multi-unit TEP absent a separate written agreement between the parties for that purpose.

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 
 
 3
 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 6. Territories. The parties acknowledge that pursuant to the Existing Agreements
various portions of the world were not allocated between the parties as exclusive Territories for exploiting the Takagi Technology and Histogenics’ Technology. The parties hereby acknowledge and agree that Histogenics shall have worldwide
rights to its products and technology and, within the Field of Use, the Takagi Technology with the sole exception that Takagi shall retain the exclusive rights to commercialize, manufacture, and sell the Histogenics Product Line in the Field of Use
in Japan. Histogenics shall cooperate with Takagi, and provide such Histogenics Technology, data and technical information, support, and assistance to Takagi, at Takagi’s sole cost and expense, in order to commercialize all or any portion of
the Histogenics Product Line in the Field of Use and to obtain the requisite governmental approvals to manufacture and sell the Histogenics Product Line in Japan from the Ministry of Health, Labour and Welfare. Prior to commercialization of the
Histogenics Product Line in Japan, Histogenics shall supply Takagi with its clinical requirements of collagen scaffolds and CT3 at ****. Upon commercialization of the Histogenics Product Line, Histogenics shall supply Takagi with such components at
****. Takagi shall be responsible for ****. Prior to commercialization of any of the products included in the Histogenics Product Line in Japan, the parties shall enter into an agreement that will address supply of components, sales and royally
reporting and payments due to third parties, audit rights of sales records, and other commercially reasonable requirements. To the extent that Takagi is assisted in the commercialization, manufacture, sale or governmental approval process of the
Histogenics Product Line or other Histogenics products in the Field of Use by third parties, Takagi agrees that it shall cause such parties to enter into appropriate nondisclosure and confidentiality agreements in such form as Histogenics shall
reasonably require. 
 7. Brigham and Women’s License. Reference is made to the existing license between Takagi and the Brigham
and Women’s Hospital, Inc. dated August 1, 2001 as amended by agreements dated December 30, 2005 and May 4, 2010 (the “B&W License”). Pursuant to the Existing Agreements,

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 
 
 4
 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Histogenics has undertaken to pay any royalties due under the B&W License to the extent that such royalties are measured by Histogenics’ revenue. Histogenics has also agreed to pay any
minimum royalties or milestone payments required by Sections 4.4 and 4.5 of the B&W License. Histogenics shall continue to honor these obligations until such time as Histogenics is no longer using the technology licensed by the B&W License.
Upon written notice from Histogenics of its intent to cease using the technology licensed by the B&W License, Takagi shall reassume all responsibility under the B&W License or, at Takagi’s option, allow the B&W License to lapse.
Histogenics shall defend, indemnify and hold Takagi harmless from any claim by or liability to ****. 
 8. Consideration. At such
time as when Histogenics enters into a transaction that would constitute an “Event of Liquidation” as defined in the **** Term Sheet (a “Liquidity Event”), then, upon the closing of such Liquidity Event, Takagi shall be paid from
the proceeds, as, if; when and “in-kind” received by Histogenics or its stockholders, the Consideration (as such term defined below). The term “Consideration” shall mean 7.8125% of the net proceeds of any Liquidity Event. In the
event that Histogenics requires financing exceeding the $48 million contemplated by the **** Term Sheet prior to a Liquidity Event, and one or more the investors (including their successors and assigns) participating in the financing contemplated by
the **** Term Sheet (the “**** Investors”) also participate in such additional financing, then the Consideration will be subject to dilution pursuant to the following formula: 

 

			
	$48M	  	x 7.8125% = New Consideration Percentage
	($48M +$x)	  

 where $x is the additional amount of equity investment beyond the $48 million contemplated by the **** Term Sheet. The
Consideration shall be paid from the net proceeds to be received by the Histogenics’ stockholders after the payment of; (a) transaction costs to unaffiliated third parties, (b) repayment of debt incurred after the Effective Date, if
any, and (c) the payment of all rights and 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 
 
 5
 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
preferences due to the **** Investors. To the extent that the stockholders of Histogenics receive payment of the purchase price from a Liquidity Event over time, such as an escrow, installment
sale or earnout, then the Consideration shall be paid as funds (whether in cash or in-kind) are actually received by the stockholders of Histogenics. At the Effective Date, the stockholders (which term in this Agreement includes the **** Investors)
shall enter into a Stockholders Agreement whereby they agree on behalf of themselves and their successors and assigns to irrevocably authorize Histogenics to pay the Consideration upon the occurrence of a Liquidity Event from the proceeds thereof
directly to Takagi in accordance with the terms hereof. 
 If, in lieu of a Liquidity Event, Histogenics shall undertake an initial public
offering of its common stock (an “IPO”) then immediately prior to the IPO Histogenics and/or its stockholders shall pay the Consideration in shares of its common stock valued at the IPO price, as determined by the Histogenics IPO pricing
committee (the “Shares”). For purposes of determining the aggregate number of Shares to be issued to Takagi in such case, Histogenics shall take its pre-IPO value as determined by the Histogenics IPO pricing committee, subtract from that
amount the transaction costs of the IPO, the amount of post-Effective Date indebtedness, if any, of Histogenics at the time and the amount of all rights and preferences of the **** Investors, and then multiply the result by the Consideration
percentage. **** 
 Subject to execution of any applicable confidentiality or nondisclosure agreement, Takagi shall have the right to
receive and review copies of the closing documentation and agreements relating to any Liquidity Event. 
  

9. Cooperation with **** Closing. Takagi agrees to cooperate with Histogenics to assist it in closing the transactions contemplated by
the **** Term Sheet including without limitation executing such documents, votes, and certificates as Histogenics or the investors in the 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 
 
 6
 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
transactions contemplated thereby may reasonably request; provided, however, that none of such documents, votes or certificates shall be inconsistent with the provisions of this Agreement. 

10. Indemnification. Each party shall indemnify, defend and hold each other and their respective directors, officers, employees and
agents, and their respective heirs, successors and assigns (the “Indemnitees”) harmless from and against any liability, damage, loss or expense (including reasonable attorney’s fees) incurred by or imposed upon the Indemnitees or any
one of them in connection with any third-party claims, suits, actions, demands or judgments arising out of ****. 
 11.
Confidentiality. Except as specified in Section 6, above, each party shall keep confidential any non-public information disclosed by or on behalf of, and belonging to, the other party in connection with this Agreement, whether marked as
proprietary or confidential, or which, by the circumstances of the disclosure, would reasonably be understood as the proprietary information of such other party, including, but not limited to all know-how, trade secrets and proprietary technical
information. The receiving party shall not disclose the other party’s confidential information to any third party and shall protect such information with the same degree of care as it uses to protect its own confidential information of similar
importance, but in no case using less than a reasonable degree of care, and may only disclose the confidential information to its affiliates, employees, agents or independent contractors on a need-to-know basis and who are bound by written
confidentiality obligations consistent with the receiving party’s obligations hereunder. The receiving party shall only use the other party’s confidential information to perform its obligations or exercise its rights under this Agreement.
If the receiving party receives a request pursuant to a court order, governmental body request or other legal process to disclose the other party’s confidential information, the receiving party will promptly notify the other party and provide
reasonable assistance to limit the scope of the required disclosure or seek a protective order. The receiving party shall not be subject to confidentiality obligations for confidential information that (a) at the time of receipt was already
known to it without confidentiality obligation; (b) becomes publicly known through no wrongful act of the receiving party; (c) was received from a third party without 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 
 
 7
 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
confidentiality restrictions; (d) is independently developed by the receiving party without use of the confidential information of the other party; or (e) is approved for release by
prior written authorization by the other party or its authorized agent. 
 12. Patent Prosecution. Each party will have the sole
right to make all decisions regarding the filing, prosecution and maintenance of its respective patents. Without limiting the foregoing, if a party does not make any filing or payment related to the prosecution or maintenance of any patent or patent
application which it owns and is licensed under this Agreement (the Takagi Patents or Histogenics Patents, as applicable) or intends not to make such payment or filing or to abandon or allow any right to any such patent or patent application to
lapse, it will promptly inform the other party, and such other Party will have the right, exercisable in its sole discretion and expense, to file or continue the prosecution or maintenance of such patent or patent application in its own name. 

13. Patent Enforcement. Each party shall promptly notify the other party of any suspected infringement by a third party of which it is
aware concerning the Takagi Patents or Histogenics Patents. **** will have the first right, but not the obligation to initiate and prosecute legal proceedings with respect to any patent **** under this Agreement (****, as applicable), at its own
expense, and to control the defense of any such action. If **** does not intend to pursue any legal proceeding, **** will promptly inform ****, and **** will have the right, but not the obligation, to initiate an action at its own cost and expense
only to the extent the potential infringement pertains to ****’s products or services covered by a patent ****. **** will reasonably cooperate with **** in any such effort, including being joined as a party to such action if necessary, at the
expense of ****. 
 14. Miscellaneous. The interpretation and application of this Agreement shall be governed by the laws of the
Commonwealth of Massachusetts, which shall also serve as the exclusive venue for the resolution of any disputes. The failure of any party to enforce at any time any provision of this Agreement or any right with respect thereto, or to exercise any
election as herein provided, shall in no 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 
 
 8
 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
way be considered to be a waiver of such provision, right or election, or in any way affect the validity of this Agreement. The exercise by any party of any right or election under the terms of
this Agreement shall not preclude or prejudice any party from exercising the same or any other right it may have under this Agreement. Neither this Agreement nor the rights or obligations under it may be assigned by either party to a third party
without the prior written consent of the other party, except that either party may assign this Agreement, or the rights or obligations under it, in connection with any merger, consolidation, sale of all or substantially all of its assets, equity or
the business to which this Agreement relates, or similar business combination. 
 15. Notices. Written notices under this Agreement
shall be addressed as follows: 
  

			
	If to Takagi:	  	Purpose Co., Ltd.
		  	Medical Technology and Business Development Department
		  	201 Nishi-Kashiwabara Shinden
		  	Fuji-shi Shizuoka 417-8505
		  	Japan
		  	Attn: ****
		
	With a copy to:	  	****
		
	If to Histogenics:	  	Histogenics Corporation
		  	830 Winter Street
		  	3rd Floor
		  	Waltham, MA 02451
		  	Attn: Patrick O’Donnell, President and CEO
		
	With a copy to:	  	Brown Rudnick LLP
		  	One Financial Center
		  	Boston, MA 02111
		  	Attn: ****

 or to such other address as either party may request in writing. Notices sent by mail, facsimile, overnight delivery or email
shall be effective if actually received. 
 16. Entire Agreement. This Agreement and the Exhibits hereto constitute the entire
agreement and understanding between the parties and neither party shall be obligated by any condition or 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 
 
 9
 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 representation other than those expressly stated herein or as may be subsequently agreed by the parties
hereto in writing. 
 17. Counterparts. This Agreement may be executed in one or more counterpart signature pages, and executed
signature pages may be delivered via facsimile or via email with PDF scan attachment, each of which shall be deemed an original but all of which together will constitute one and the same instrument. 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as an instrument under seal by their duly authorized
representatives. 
  

									
	PURPOSE CO., LTD.,	 		 	HISTOGENICS CORPORATION
	F/K/A TAKAGI SANGYO CO., LTD. AND	 		 		 	
	F/K/A TAKAGI INDUSTRIAL CO., LTD.	 		 		 	
					
	By:	 	 /s/ Chiharu Ishikawa
	 		 	By:	 	 /s/ Patrick O’Donnell

	Name:	 	 Chiharu Ishikawa
	 		 	Name:	 	 Patrick O’Donnell

	Title:	 	 Executive Director
	 		 	Title:	 	 President & CEO

	Date:	 	 June 25, 2012
	 		 	Date:	 	 June 25, 2012

  

  
 
 10
 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT A 

**** TERM SHEET 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 CONFIDENTIAL TERM SHEET 

FOR PROPOSED INVESTMENT IN 

HISTOGENICS CORPORATION 
 This Term
Sheet summarizes the terms and conditions of a proposed investment by **** through its affiliates in Histogenics Corporation It is for discussion purposes only and, except to the extent set forth herein, is not binding upon any party. Specific
provision(s) may be made binding upon the parties by explicitly so stating within this Term Sheet. Neither party is obligated to consummate an investment unless and until a definitive investment agreement has been mutually agreed to and executed by
the parties **** will serve as the lead investor for this financing. 
 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 2 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 3 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 4 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 5 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 6 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 7 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 8 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 9 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 10 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

[Signature Page Follows] 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 11 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

					
	Accepted by Histogenics Corporation:	 		 	Accepted by ****:
			
	 /s/ Patrick O’Donnell
                            2-28-12
	 		 	 /s/ ****
                                    2/14/12

	Signature
                                         
               Date	 		 	Signature
                                         
           Date
			
	 Patrick O’Donnell
	 		 	 ****

	Printed Name	 		 	Printed Name
			
	 President & CEO
	 		 	  

	Position	 		 	Position

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 12 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT B-1 

TAKAGI PATENTS 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT B-1 

TAKAGI PATENTS* 

**** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

2 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

3 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

4 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

5 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

6 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

7 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

8 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT B-2 

HISTOGENICS PATENTS 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT B-2 

HISTOGENICS PATENT 

**** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT C 

SERVICE AND MAINTENANCE AGREEMENT 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 PURPOSE CO., LTD. EQUIPMENT MAINTENANCE AGREEMENT 

Agreement No. PM12001 
 This
Agreement, effective this      day of July, 2012, made and entered into by and between 
 Purpose Co.,
Ltd.                Hereinafter called “Provider” and 

Histogenics Corporation    Hereinafter called “Customer”. 

 

			
	PROVIDER:	  	
	 Address:
 3508 Aza-mikaeshi Kamiide,

Fujinomiya, Shizuoka. 418-0103
 JAPAN
	  	 Phone:****
 Fax:****

Contact:****
 Email:****

		
	CUSTOMER:	  	
	 Address:
 830 Winter St.

3rd Floor
 Waltham, MA 02145

USA
	  	 Phone: ****
 Fax: ****

Contact: ****
 Email: ****

  

	1.	This Agreement supersedes and replaces all prior service and maintenance agreements between the parties. 

  

	2.	Customer, for the full, complete and faithful performance of this Agreement, agrees to pay Provider in accordance with the rates and prices as stated herein, and Provider, for the rates and prices stated herein, agrees
to perform the services set forth herein. 

  

	3.	Equipment Covered by this Agreement (the “Equipment”). 

 Refer to EXHIBIT A. As
Customer purchases new Equipment from Provider, such Equipment shall automatically be deemed included on Exhibit A. 
  

	4.	Place of Servicing. The Equipment is to be serviced at 830 Winter Street, 3rd Floor, Waltham, MA 02145. (“Permanent Installation Location”) or such other location as Customer may elect by notice to
Provider. 

  

	5.	Term. Unless earlier terminated in accordance with the terms hereof, this Agreement shall be in effect from the date hereof, and shall automatically and continually renew for additional one year periods (the
“Term”) until such date as Customer elects to terminate by giving thirty (30) days prior notice to Provider. 

  

	6.	Type of Service. 

  

	 	a.	 Preventive Maintenance Service. During the Term, Customer shall receive from Provider preventive maintenance service for the Equipment at
regular intervals, twice every twelve 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 1 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	
month period (“PM Service”). Customer will provide written notice to Provider requesting PM Service, and following such request, the Customer and Provider will agree upon a mutually
convenient date(s) and time(s) for the performance of the PM Service, provided that in no event shall such PM Service be performed by Provider later than sixty (60) days after Customer’s request. The services to be performed during the PM
Service are set forth in Section 7 below. 

  

	 	b.	Additional Service. In addition to the PM Service, upon request from Customer, Provider shall provide Customer with such additional services for the Equipment, including emergency repair services
(“Additional Service”), as set forth in Section 8 below. 

  

	 	c.	Technical Assistance. Provider shall provide Customer, at no additional cost, any information and technical specifications and assistance concerning the Equipment that Customer may require in connection with
pursuing any governmental approvals for Customer’s products, including without limitation the U.S. Food and Drug Administration. 

  

	7.	Rates for Maintenance. 

  

	 	a.	Preventive Maintenance Service. **** per year for each TEP and up to two (2) TCUs. In addition, Provider shall be reimbursed its reasonable travel expenses, including airfare, ground transportation, hotel, and
meals, and any related taxes, for each PM Service visit (“PM Service Rate”). 

  

	 	b.	Rate for Additional Service. **** per hour at Provider’s location or **** per hour at any Permanent Installation Location, plus associated travel expenses and any taxes (“Additional Rate”).

  

	8.	PM Service to be Performed by Provider. 

 Provider agrees to provide the inspection and
PM Service according to the check list and protocol developed by Provider. Price quote of replacement parts will be provided to the Customer prior to each PM Service or Additional Service. A CHARGE WILL BE MADE FOR ANY PARTS REPLACED AT AN AMOUNT
EQUAL TO THE PROVIDER’S STANDARD PRICING. Labor involved in repairing damage due to Customer mishandling, or improper operation of the Equipment will be charged at Additional Rate as provided in paragraph 6(b) of this Agreement. 

There is no warranty to PM by Provider. Provider warrants the replacement parts within the range of Additional Service. 

 

	9.	Additional Service to be Performed by Provider. 

 Provider agrees to provide the
following Additional Services upon receipt of a request from Customer: 
  

	 	•	 	the inspection, testing and diagnostic evaluation (either on site or remotely) by the Provider; 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 2 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	•	 	any fault reporting and resolving in an item of the Equipment; 

  

	 	•	 	the repair or replacement of parts; 

  

	 	•	 	reinstallation of the Equipment. 

 Provider will promptly evaluate each Additional Service
request received from Customer to determine if servicing can be addressed remotely. If on-site service is required the Provider will send a technician to the Customer within fourteen (14) days of requesting the on-site service. 

A price quote for replacement parts will be provided to the Customer prior to this service. A CHARGE WILL BE MADE FOR ANY PARTS REPLACED AT AN
AMOUNT EQUAL TO THE PROVIDER’S STANDARD PRICING. 
 Provider warrants that the repairs will remain in good working order and repair for
a period of twelve (12) months following the repair. 
  

	10.	Payment Terms. Provider shall invoice Customer for each PM Service and Additional Service separately. Customer’s payment shall be due net thirty (30) days from the invoice date. Upon request of Customer,
Provider shall provide reasonable supporting documentation with respect to any invoice issued to Customer. 

  

	11.	Renewal. Unless terminated by either party as set forth below, Provider shall be entitled to increase its rates for maintenance no more often than every 12 months and in any event no more than **** per annum.
Provider shall give Customer no less than sixty (60) days prior notice of any rate increase and will forward to Customer the rates that will take effect in the new term. 

 

	12.	Termination. Customer may terminate this Agreement at any time following thirty (30) days written notice. Provider shall have no right to terminate this Agreement except in the case of (i) Customer’s breach
of its obligations hereunder to Provider after thirty (30) days’ notice to Customer and Customer’s failure to cure such breach within such time period, (ii) Customer’s bankruptcy, insolvency, or assignment for the benefit of
creditors, or (iii) Customer’s sale or cessation of business operations. 

  

	13.	Warranty. Provider warrants that it shall have and maintain sufficient resources, facilities, capacity and manpower to assure that the services under this Agreement are diligently performed in accordance with the
terms and conditions of this Agreement in a timely, skillful, professional, workmanlike and competent manner, by qualified persons familiar with the Equipment and fully trained to service the Equipment, and that the services provided shall conform
to or exceed the standards generally observed in the industry for similar services. Notwithstanding the foregoing, Provider does not guaranty that damaged or worn Equipment will be successfully repaired or that all unique replacement parts for the
Equipment will be readily available. 

  

	14.	 Notices. All notices or other communications which are required or permitted hereunder shall be in writing and sufficient if delivered by hand,
by facsimile transmission, by electronic mail, by registered or certified mail, postage pre-paid, or by courier or 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 3 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	
overnight carrier, to the applicable party at the addresses set forth above (or at such other address as may be provided hereunder), and shall be deemed to have been delivered (a) on the date of
delivery if delivered personally, or by telecopy, facsimile or electronic mail, upon confirmation of receipt of delivery, (b) on the second business day following the date of dispatch if delivered by a nationally recognized next-day courier service,
or (c) on the fifth business day following the date of mailing if delivered by registered or certified mail return receipt requested, postage prepaid. 

  

	15.	Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the Commonwealth of Massachusetts, without regard to principles of conflicts of law. 

 

	16.	Amendment. No amendment of any provision of this Agreement shall be effective unless the same shall be in writing and signed by the Customer and the Provider. 

 

	17.	No Waiver. The waiver or failure of either party to exercise any right provided for herein shall not be deemed a waiver of any further right hereunder. 

 

	18.	Relationship of Parties. The performance by Provider of its duties and obligations under this Agreement shall be that of an independent contractor, and nothing herein shall create or imply an agency relationship
between Provider and Customer, nor shall this Agreement be deemed to constitute a joint venture or partnership between the parties. Personnel supplied by Provider shall not be considered employees or agents of Customer for any purpose. Provider
assumes full responsibility for the acts of such personnel while performing the Services and shall be solely responsible for such personnel’s supervision, direction and control, compensation, benefits and taxes. 

 

	19.	Severability. The invalidity or unenforceability of any one or more phrases, sentences, clauses, paragraphs, or sections contained in this Agreement shall not affect the validity or enforceability of the
remaining portions of this Agreement hereof. 

  

	20.	Successors and Assigns. This Agreement shall apply in all respects to successors and permitted assigns of Provider and inure to the Customer and its successors and permitted assigns. This Agreement shall not be
assignable either in whole or in part by either of the parties without a prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed. 

 

	21.	Entire Agreement. This Agreement contains the entire agreement of the Customer and Provider with respect to the matters set forth herein. 

 

	22.	Counterparts. This Agreement may be executed in counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the
parties and delivered to the other party. Facsimile transmission of any signed original document shall be deemed the same as delivery of an original. 

IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized representatives: 

  
 - 4 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

									
	Authorized Representative for Provider	 		 	Authorized Representative for Customer
			
	PURPOSE CO., LTD.	 		 	HISTOGENICS CORPORATION
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

  
 - 5 - 

 EXHIBIT A 

Equipment List 
  

							
	 	  	 Equipment Description
	  	 Serial Number
	  	 Histogenics Equipment Number

	1	  	TEP-P02	  	TEP-P02-07	  	EQ-115
	2	  	TEP-P02	  	TEP-P02-08	  	EQ-116
	3	  	TEP-P02	  	TEP-P02-09	  	EQ-117
	4	  	TEP-P02	  	TEP-P02-10	  	EQ-118
	5	  	 TEP-P02
	  	TEP-P02-11	  	EQ-290
	6	  	TEP-P02	  	TEP-P02-12	  	EQ-194
	7	  	TEP-P02	  	TEP-P02-13	  	EQ-195
	8	  		  		  	
	9	  		  		  	
	10	  		  		  	
	11	  		  		  	
	12	  		  		  	
	13	  		  		  	
	14	  		  		  	
	15	  		  		  	
	16	  		  		  	
	17	  		  		  	
	18	  		  		  	
	19	  		  		  	
	20	  		  		  	
	21	  		  		  	
	22	  		  		  	
	23	  		  		  	
	24	  		  		  	
	25	  		  		  	
	26	  		  		  	
	27	  		  		  	
	28	  		  		  	
	 29
	  		  		  	
	 30
	  		  		  	

  
 - 6 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]